Delivery Order SPE2DB24D1006-SPE2DB25FCEZJ
- Not listed
- The Defense Logistics Agency awarded a $1,293.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside contract was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,349.15 to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (60 units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive set-aside contract and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $18,986.97 to AmerisourceBergen Drug Corp for the supply of Restasis 0.05% Eye Emulsion (30-count units). This competitively awarded, firm fixed-price delivery order is scheduled for completion by December 3, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among qualified pharmaceutical distributors....
- The Defense Logistics Agency awarded a $1,117.68 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (60 count) on July 22, 2025, with an ultimate completion date of July 23, 2025. This firm fixed price delivery order represents a non-competitive set-aside contract and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $5,990.32 to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30-count units) on September 23, 2025, with an ultimate completion date of September 24, 2025. The contract utilizes firm fixed price terms with no set-aside designation, indicating competitive award through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,256.36 to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60 units) on January 29, 2026, with completion expected by January 30, 2026. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a $2,256.45 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% eye emulsion (30-unit pack) on November 28, 2025, with completion targeted for December 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The contractor will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $1,340.35 to AmerisourceBergen Drug Corp for supply of Restasis 0.05% Eye Emulsion (60 count) on January 15, 2026, with a completion date of January 16, 2026. This firm fixed-price delivery order was competitively awarded without set-aside designation and is being performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical...
- The Defense Logistics Agency awarded a $3,930.90 delivery order to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (30 single-dose units) on December 19, 2025, with an ultimate completion date of December 22, 2025. This is a firm fixed-price, non-set-aside contract issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Restasis 0.05% eye emulsion in 60-count units. This non-competitive delivery order, valued at $11,404.78, was executed on October 20, 2025, with an ultimate completion date of October 21, 2025. The contract employs firm fixed pricing and represents a direct fulfillment of pharmaceutical needs within the...
- SPE2DB24D1006Indefinite Delivery Contract
- SPE2DB24D1006-SPE2DB25FCEZJDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,275.21 to AmerisourceBergen Drug Corp for Restasis 0.05% Eye Emulsion (60-count), with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, is well-positioned to fulfill this requirement as a critical federal medical procurement vendor. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime contract vehicle running through December 2026 that enables comprehensive pharmaceutical support for military healthcare programs worldwide. The IDC encompasses a wide range of pharmaceutical products, medical supplies, vaccines, and specialty medications across multiple therapeutic domains, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The current delivery order represents a routine drawdown of pharmaceutical inventory in support of federal medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/5/25 |